PWM
FDMT icon

Perigon Wealth Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Perigon Wealth Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Buy
146,197
+64
+0% +$557 0.02% 451
2025
Q4 		$1.1M Hold
146,133
– – 0.02% 512
2025
Q3 		$1.27M Hold
146,133
– – 0.03% 448
2025
Q2 		$542K Hold
146,133
– – 0.01% 646
2025
Q1 		$472K Hold
146,133
– – 0.01% 655
2024
Q4 		$684K Sell
146,133
-37
-0% -$290 0.02% 550
2024
Q3 		$1.58M Hold
146,170
– – 0.04% 326
2024
Q2 		$3.07M Buy
146,170
+20
+0% +$502 0.09% 199
2024
Q1 		$4.66M Sell
146,150
-100,000
-41% -$2.55M 0.14% 151
2023
Q4 		$4.99M Hold
246,150
– – 0.16% 130
2023
Q3 		$3.13M Buy
246,150
+75
+0% +$1.25K 0.13% 157
2023
Q2 		$4.45M Hold
246,075
– – 0.17% 126
2023
Q1 		$4.23M Hold
246,075
– – 0.24% 94
2022
Q4 		$5.47M Sell
246,075
-4,400
-2% -$68K 0.34% 72
2022
Q3 		$2.01M Sell
250,475
-98,271
-28% -$890K 0.17% 121
2022
Q2 		$2.43M Sell
348,746
-208,729
-37% -$2.03M 0.2% 104
2022
Q1 		$8.43M Sell
557,475
-209,492
-27% -$3.29M 0.6% 30
2021
Q4 		$16.8M Buy
+766,967
New +$18.8M 1.2% 13

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perigon Wealth Management's FDMT Position: Q1 2026 in Review

Perigon Wealth Management increased its 4D Molecular Therapeutics (FDMT) stake by 0.04% in Q1 2026, buying an estimated $557 and bringing the position to 146,197 shares worth $1.36M. The position accounts for 0.02% of the portfolio, ranked #451.

Perigon Wealth Management first reported a position in FDMT in Q4 2021 and has held it in 18 quarters since. The position peaked at $16.8M in Q4 2021. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Perigon Wealth Management held 146,197 shares of 4D Molecular Therapeutics worth $1.36M as of Q1 2026.
  • Perigon Wealth Management bought 64 4D Molecular Therapeutics shares in Q1 2026, an estimated $557.
  • 4D Molecular Therapeutics made up 0.02% of Perigon Wealth Management's portfolio in Q1 2026, its #451 holding.
  • Perigon Wealth Management first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Perigon Wealth Management's 4D Molecular Therapeutics position peaked at $16.8M in Q4 2021.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.